{"disease":{"id":"mydriasis","name":"mydriasis"},"drugs":{"marketed":[{"drug_id":"dapiprazole","indication_name":"Reverse Mydriasis from Ophthalmic Adrenergic or Anticholinergic Agent","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Dapiprazole Hydrochloride","generic_name":"DAPIPRAZOLE","company_name":"Fera Pharms","drug_phase":"marketed","molecular_target":"Alpha-1D adrenergic receptor","drug_class":"alpha-Adrenergic Blocker","quality_score":24,"revenue":null,"mechanism":""},{"drug_id":"atropin","indication_name":"Perioperative Mydriasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Enlon-Plus","generic_name":"Atropin","company_name":"Alcon Labs Inc","drug_phase":"marketed","molecular_target":"Muscarinic acetylcholine receptor M3","drug_class":"Non-Standardized Insect Allergenic Extract [EPC]","quality_score":49,"revenue":null,"mechanism":""},{"drug_id":"cyclopentolate","indication_name":"Perioperative Mydriasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cyclogyl","generic_name":"CYCLOPENTOLATE","company_name":"Alcon Labs Inc","drug_phase":"marketed","molecular_target":"Muscarinic acetylcholine receptor M3","drug_class":"cyclopentolate","quality_score":42,"revenue":null,"mechanism":""},{"drug_id":"phenylephrine","indication_name":"Maintenance of intraoperative mydriasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Sudafed PE","generic_name":"phenylephrine","company_name":"Generic (multiple manufacturers)","drug_phase":"marketed","molecular_target":"Alpha-1A adrenergic receptor, Alpha-1B adrenergic receptor, Alpha-1D adrenergic receptor","drug_class":"Alpha-1 adrenergic agonist (decongestant/vasopressor)","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"phenylephrine-bitartrate","indication_name":"Maintenance of intraoperative mydriasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Phenergan Vc W/ Codeine","generic_name":"PHENYLEPHRINE BITARTRATE","company_name":"ANI Pharmaceuticals","drug_phase":"marketed","molecular_target":"Alpha-1B adrenergic receptor","drug_class":"Nonsteroidal Anti-inflammatory Drug [EPC]","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"lomotil","indication_name":"Perioperative Mydriasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Enlon-Plus","generic_name":"Atropine Sulfate","company_name":"Alcon Labs Inc","drug_phase":"marketed","molecular_target":"Muscarinic acetylcholine receptors","drug_class":"Antimuscarinic agent","quality_score":62,"revenue":null,"mechanism":"Atropine antagonizes muscarine-like actions of acetylcholine through competitive antagonism at peripheral muscarinic receptors."},{"drug_id":"atropine","indication_name":"Perioperative Mydriasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Enlon-Plus","generic_name":"ATROPINE","company_name":"Mmt","drug_phase":"marketed","molecular_target":"Muscarinic acetylcholine receptor M3","drug_class":"Anticholinergic","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"homatropine","indication_name":"Perioperative Mydriasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Homatropin","generic_name":"homatropine","company_name":"","drug_phase":"marketed","molecular_target":"Muscarinic acetylcholine receptor M4","drug_class":"Cholinergic Muscarinic Antagonist","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"scopolamin","indication_name":"Perioperative Mydriasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"scopolamin","company_name":"University Hospital, Angers","drug_phase":"marketed","molecular_target":"Muscarinic acetylcholine receptor M1, Muscarinic acetylcholine receptor M2, Muscarinic acetylcholine receptor M3","drug_class":"","quality_score":null,"revenue":null,"mechanism":null}],"pipeline":[],"offLabel":[],"totalMarketed":9,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05134974","title":"Safety and Efficacy of Nyxol (0.75% Phentolamine Ophthalmic Solution) to Reverse Pharmacologically-Induced Mydriasis (MIRA-3)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":368,"lead_sponsor_name":"Ocuphire Pharma, Inc.","has_results":true},{"nct_id":"NCT04620213","title":"Safety and Efficacy of Nyxol (0.75% Phentolamine Ophthalmic Solution) to Reverse Pharmacologically-Induced Mydriasis","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":185,"lead_sponsor_name":"Ocuphire Pharma, Inc.","has_results":true},{"nct_id":"NCT03751098","title":"Safety and Efficacy of Phenylephrine 2.5%-Tropicamide 1% Microdose Ophthalmic Solution for Pupil Dilation","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":76,"lead_sponsor_name":"Eyenovia Inc.","has_results":true},{"nct_id":"NCT03751631","title":"Safety and Efficacy of Phenylephrine 2.5%-Tropicamide 1% Microdose Ophthalmic Solution for Pupil Dilation","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":70,"lead_sponsor_name":"Eyenovia Inc.","has_results":true},{"nct_id":"NCT05880433","title":"The Effects of Mydriatic Eye Drops in Retinopathy of Prematurity Examinations","phase":"","overall_status":"COMPLETED","enrollment_count":62,"lead_sponsor_name":"Istanbul Training and Research Hospital","has_results":false},{"nct_id":"NCT04907474","title":"Evaluation of Pupil Dilation Speed With the MAP Dispenser","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":61,"lead_sponsor_name":"Eyenovia Inc.","has_results":true},{"nct_id":"NCT04024891","title":"Safety and Efficacy of Ophthalmic Phentolamine Mesylate to Reverse Pharmacologically Induced Mydriasis","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":32,"lead_sponsor_name":"Ocuphire Pharma, Inc.","has_results":true},{"nct_id":"NCT04396301","title":"Effect of Intracameral Injection of Mydriatic Plus Anaesthetic Combination on Corneal Endothelial Count in Phaco","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":30,"lead_sponsor_name":"Cairo University","has_results":false},{"nct_id":"NCT06217796","title":"Safety and Efficacy of Fixed Combination Phenylephrine-Tropicamide for Pupil Dilation","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":30,"lead_sponsor_name":"Eyenovia Inc.","has_results":true},{"nct_id":"NCT05223478","title":"Nyxol (0.75% Phentolamine Ophthalmic Solution) to Reverse Pharmacologically-Induced Mydriasis in Pediatric Subjects","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":23,"lead_sponsor_name":"Ocuphire Pharma, Inc.","has_results":true},{"nct_id":"NCT05829122","title":"Sutureless Intrascleral Intraocular Lens Fixation and Modified Iris Cerclage Pupilloplasty","phase":"NA","overall_status":"UNKNOWN","enrollment_count":20,"lead_sponsor_name":"Changzhou Second People's Hospital affiliated with Nanjing Medical University","has_results":false},{"nct_id":"NCT07075224","title":"Pharmacodynamics of a Fixed Dose Combination of 0.34% Tropicamide and 2.5% Phenylephrine Hydrochloride, Eye Drop, Solution","phase":"PHASE1, PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":20,"lead_sponsor_name":"Unither Pharmaceuticals, France","has_results":false}],"total":12},"guidelines":[],"source":"Drug Landscape verified database"}